Drug Pricing
Our work in Drug Pricing
-
​Are State Medicaid Policies Sentencing People with Mental Illnesses to Prison?
Researchers have linked tighter Medicaid policies governing antipsychotic drugs with increased incarceration rates for schizophrenic individuals.
Categorized in -
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies
This study developed a general cost-benefit framework that quantified the competing tradeoffs of the use of progression-free survival versus that of overall survival effects in oncology reimbursement.
Categorized in -
Assessment of Therapeutic Preferences and Ideal Treatment Attributes among Adults with Cystic Fibrosis
This study identified treatment attributes and assessed preferences between two formulations of inhaled therapies as reported by adults with cystic fibrosis, and found that patients overwhelmingly expressed preference for a dry powder formulation of a chronic inhaled medication, which may lead to improved adherence and quality of life.
Categorized in -
Nudging Guideline-Concordant Antibiotic Prescribing: A Randomized Clinical Trial
This study found that displaying poster-sized commitment letters in examination rooms decreased inappropriate antibiotic prescribing for acute respiratory infections, and that the effect of this simple, low-cost intervention is comparable in magnitude to costlier, more intensive quality-improvement efforts.
Categorized in -
Early HIV Treatment Led to Life Expectancy Gains Valued at $80 Billion for People Infected in 1996–2009.
This study analyzed the life expectancy gains of people infected with HIV between the introduction of cART in 1996 and the 2009 guideline revisions, and found that, compared to people who initiated cART late (defined as having a CD4 cell count of less than 350 per cubic millimeter of blood), those who initiated treatment early (with a CD4 count of 350–500) could expect to live 6.1 years longer, and the earliest initiators (with a CD4 count of more than 500) could expect an extra 9.0 years of life.
Categorized in -
Early HIV Treatment In The United States Prevented Nearly 13,500 Infections Per Year During 1996–2009
This study assessed HIV prevention through initiation of combination antiretroviral therapy (cART) when CD4 white blood cell counts are in excess of 350 cells per cubic millimeter and found that the timing of treatment initiation in the US prevented 188,000 HIV cases in the period 1996–2009.
Categorized in -
Careful Use of Science to Advance the Debate on the UK Cancer Drugs Fund
This article considers the debate over the recent renewal of the UK Cancer Drugs Fund, which sets aside money for the National Health Service to pay for expensive oncology medications that have not been recommended for coverage.
Categorized in -
Digesting the Doughnut Hole
Joyce, Zissimopoulos, and Goldman compare the use of prescription drugs among beneficiaries subject to the coverage gap (also known as the doughnut hole) with usage among beneficiaries who are not exposed to it.
Categorized in -
Quintiles Seminar Series – Fall: Sep-Dec 2013
The Quintiles Seminar Series is a biweekly seminar series that features prominent academics, researchers, policy makers, and industry leaders to discuss prevalent and current themes in health, policy, and economics.
Categorized in -
What Healthcare Can Learn from Netflix
The trick here is to think of pharmaceuticals as any other consumer good where there are high fixed costs and low marginal costs.
Categorized in